Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EQ Equillium Inc

0.2396 (8.68%)
Feb 20 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 1,126,015
Bid Price 2.82
Ask Price 3.00
News -
Day High 3.0899


52 Week Range


Day Low 2.40
Company Name Stock Ticker Symbol Market Type
Equillium Inc EQ NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.2396 8.68% 2.9996 19:10:05
Open Price Low Price High Price Close Price Prev Close
2.76 2.40 3.0899 3.00 2.76
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,676 1,126,015 $ 2.81 $ 3,159,278 - 0.45 - 3.0899
Last Trade Time Type Quantity Stock Price Currency
19:43:40 43 $ 3.00 USD

Equillium Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
105.36M 35.12M - 15.76M -62.43M -1.78 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Equillium News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No EQ Message Board. Create One! See More Posts on EQ Message Board See More Message Board Posts

Historical EQ Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.583.08991.282.27651,8131.4289.85%
1 Month0.753.08990.72051.52634,8462.25299.95%
3 Months0.49033.08990.4788991.24323,6812.51511.79%
6 Months0.85743.08990.451.10187,6872.14249.85%
1 Year1.103.08990.450.9125374184,9511.90172.69%
3 Years9.159.510.452.74139,470-6.15-67.22%
5 Years6.8930.200.4514.89403,151-3.89-56.46%

Equillium Description

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Your Recent History

Delayed Upgrade Clock